U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H30O11
Molecular Weight 494.4884
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of HARPAGOSIDE

SMILES

[H][C@]12[C@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)OC=C[C@@]1(O)[C@H](O)C[C@]2(C)OC(=O)\C=C\C4=CC=CC=C4

InChI

InChIKey=KVRQGMOSZKPBNS-FMHLWDFHSA-N
InChI=1S/C24H30O11/c1-23(35-16(27)8-7-13-5-3-2-4-6-13)11-15(26)24(31)9-10-32-22(20(23)24)34-21-19(30)18(29)17(28)14(12-25)33-21/h2-10,14-15,17-22,25-26,28-31H,11-12H2,1H3/b8-7+/t14-,15-,17-,18+,19-,20-,21+,22+,23+,24-/m1/s1

HIDE SMILES / InChI

Molecular Formula C24H30O11
Molecular Weight 494.4884
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 10
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.scbt.com/scbt/product/harpagoside-19210-12-9

Harpagoside is an anti-inflammatory small molecule natural product originally isolated from the Harpagophytum procumbens (Devil's Claw) root, but can be isolated from other plants such as Crophularia ningpoensis Hemsl (Figwort). Treatment of HepG2 cells with Harpagoside demonstrated suppression of NF-κB nuclear translocation and degradation of IκB-α, blocking NF-κB activation. Multiple anti-inflammatory cellular effects were correlated with this blockade, as Harpagoside was observed to inhibit the expression of inflammation-mediating enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and to reduce lipopolysaccharide-induced mRNA levels. The suppression of NF-κB activation is indicated as the mechanism beneath the anti-inflammatory effects of Harpagoside. Harpagoside is widely used as a folk remedy to treat rheumatic complaints.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
39.8 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation.
2006 Mar 8
Patents

Sample Use Guides

Devil's claw has been studied for low back pain, muscle pain, and osteoarthritis using daily doses of crude tuber up to 9 g, 1 to 3 g of extract, or harpagoside 50 to 100 mg.
Route of Administration: Oral
Harpagoside (200uM) significantly inhibited the induction of COX-2 and iNOS mRNA and their corresponding protein expression in LPS-treated HepG2 cells
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:43:13 GMT 2023
Edited
by admin
on Fri Dec 15 19:43:13 GMT 2023
Record UNII
8KGS1DC5ZU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HARPAGOSIDE
INCI   WHO-DD  
INCI  
Official Name English
E-HARPAGOSIDE
Common Name English
.BETA.-D-GLUCOPYRANOSIDE, (1S,4AS,5R,7S,7AS)-1,4A,5,6,7,7A-HEXAHYDRO-4A,5-DIHYDROXY-7-METHYL-7-(((2E)-1-OXO-3-PHENYL-2-PROPENYL)OXY)CYCLOPENTA(C)PYRAN-1-YL
Common Name English
Harpagoside [WHO-DD]
Common Name English
HARPAGOSIDE [INCI]
Common Name English
Code System Code Type Description
WIKIPEDIA
Harpagoside
Created by admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
PRIMARY
RXCUI
2048124
Created by admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
PRIMARY
SMS_ID
100000145924
Created by admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
PRIMARY
EVMPD
SUB124742
Created by admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
PRIMARY
PUBCHEM
5281542
Created by admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
PRIMARY
EPA CompTox
DTXSID101032528
Created by admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
PRIMARY
CAS
19210-12-9
Created by admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
PRIMARY
ECHA (EC/EINECS)
242-881-6
Created by admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
PRIMARY
FDA UNII
8KGS1DC5ZU
Created by admin on Fri Dec 15 19:43:13 GMT 2023 , Edited by admin on Fri Dec 15 19:43:13 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> POSSIBLE ACTIVE CONSTITUENT ALWAYS PRESENT
ASSAY (HPLC)
PARENT -> CONSTITUENT ALWAYS PRESENT
Related Record Type Details
ACTIVE MOIETY